retatrutide what is Retatrutide: The New Triple-Agonist Weight

Sa1950 impact of GLP1 agonists on inflammatory biomarkers in patients with inflammatory bowel disease

The mechanism of action does not directly involve the coagulation cascade or platelet function, which has led to questions about whether these medications might influence thrombotic risk

Available from: Accessed 1 Mar 2023 Brown E, Heerspink HJL, Cuthbertson DJ, Wilding JPH (2021) SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications

The authors concluded: The use of GLP-1 agonists should be considered in T1DM patients who are overweight or obese and not at glycemic goals despite aggressive insulin therapy. After conducting clinical trials with a GLP-1 agonist, Novo Nordisk decided not to pursue FDA approval for treating type 1 diabetes

The challenge is that sleep biology is complex

fasted AM pre-workout is second best Wait 2030 min post-injection before eating With CJC+DAC: Pin CJC+DAC 1mg once weekly Pin Ipamorelin 100200mcg 2-3x/week separately (or co-pin with the CJC injection) --- Stacking with Retatrutide or GLP-1s The combination of CJC+Ipa and Retatrutide (or Tirzepatide/Semaglutide) is one of the most effective recomposition stacks currently used: Reta/GLP-1 handles appetite regulation, insulin sensitivity, and GLP-1/GIP/glucagon receptor activity CJC+Ipa drives GH pulses IGF-1 muscle protein synthesis + overnight fat mobilization Combined: accelerated fat loss + lean mass retention simultaneously For this combination, Mod GRF 1-29 (no DAC) is generally preferred over CJC+DAC because the pulsatile pattern complements the continuous metabolic effect of GLP-1s cleanly without creating sustained GH elevation